TG Therapeutics, Inc. (TGTX) Earnings History
Annual and quarterly earnings data from 1996 to 2025
Loading earnings history...
TGTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TGTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 83.7% | 20.0% | 72.6% |
| 2024 | 88.3% | 12.7% | 7.1% |
| 2023 | 94.0% | 8.8% | 5.4% |
| 2022 | 90.5% | -7839.0% | -8036.3% |
| 2021 | 88.2% | -5154.3% | -5204.1% |
Download Data
Export TGTX earnings history in CSV or JSON format
Free sign-in required to download data
TG Therapeutics, Inc. (TGTX) Earnings Overview
As of May 9, 2026, TG Therapeutics, Inc. (TGTX) reported trailing twelve-month net income of $462M, reflecting +1746.7% year-over-year growth. The company earned $2.89 per diluted share over the past four quarters, with a net profit margin of 72.6%.
Looking at the long-term picture, TGTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $447M in fiscal 2025, representing a new all-time high.
TG Therapeutics, Inc. maintains industry-leading profitability with a gross margin of 83.7%, operating margin of 20.0%, and net margin of 72.6%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), IMVT (-$464M net income), PRAX (-$327M net income), TGTX has outperformed on profitability metrics. Compare TGTX vs RCUS →
TGTX Earnings vs Peers
Earnings metrics vs comparable public companies
TGTX Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $447M | +1812.4% | $123M | $2.77 | 72.6% | 20.0% |
| 2024 | $23M | +84.5% | $42M | $0.15 | 7.1% | 12.7% |
| 2023 | $13M | +105.7% | $21M | $0.09 | 5.4% | 8.8% |
| 2022 | -$224M | +35.7% | -$218M | $-1.46 | -8036.3% | -7839.0% |
| 2021 | -$348M | -24.6% | -$345M | $-2.63 | -5204.1% | -5154.3% |
| 2020 | -$279M | -61.6% | -$274M | $-2.42 | -183803.3% | -179996.1% |
| 2019 | -$173M | +0.4% | -$169M | $-1.96 | -113730.9% | -111220.4% |
| 2018 | -$173M | -46.4% | -$174M | $-2.30 | -114132.9% | -114736.8% |
| 2017 | -$118M | -51.4% | -$119M | $-1.91 | -77749.9% | -77904.6% |
| 2016 | -$78M | -24.3% | -$79M | $-1.60 | -51353.4% | -51823.5% |
See TGTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TGTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TGTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTGTX — Frequently Asked Questions
Quick answers to the most common questions about buying TGTX stock.
Is TGTX growing earnings?
TGTX EPS is $2.89, with earnings growth accelerating to +1746.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $462M.
What are TGTX's profit margins?
TG Therapeutics, Inc. net margin is +72.6%, with operating margin at +20.0%. Above-average margins indicate pricing power.
How consistent are TGTX's earnings?
TGTX earnings data spans 1996-2025. The accelerating earnings trend is +1746.7% YoY. Historical data enables comparison across business cycles.